Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Subscribe To Our Newsletter & Stay Updated
